Tuesday, November 12, 2019 1:33:11 PM
https://www.bamsec.com/filing/161577418007286/3?cik=844985
That could be some significant dilution from our current low O/S. With the current share price @ $0.14, the 45% discount would price shares @ $0.077, which would amount to 16,542,545 shares being issued (not accounting for any interest on the note).
I've been told the note holders are "friendly" to current shareholders, appreciate the value of tight capital structure, and are not going to look to play manipulative games with the stock price prior to conversion.
All that being said, I still really like this company's potential once Lantheus's Flurpiridaz F-18 imaging agent gets approval, which is expected in about a year, and will probably give PET a distinctive advantage over SPECT for imaging accuracy/price/ and half life (allowing exercise induced stress):
http://www.lantheus.com/pipeline/flurpiridaz-f-18/
"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM